INGN 234

Drug Profile

INGN 234

Alternative Names: p53 gene therapy - Introgen/Colgate-Palmolive; p53 topical - Introgen/Colgate-Palmolive

Latest Information Update: 18 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Introgen Therapeutics
  • Class
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Leucoplakia; Orofacial cancer

Most Recent Events

  • 18 Feb 2010 Discontinued - Phase-II for Leucoplakia in USA (Buccal)
  • 18 Feb 2010 Discontinued - Phase-II for Orofacial cancer in USA (Buccal)
  • 26 Aug 2008 Phase-II clinical trials in Leucoplakia in USA (Buccal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top